FY26 results show modest revenue growth and improved cash position, but the company remains unprofitable with significant share dilution (38% increase in shares outstanding). Monitor partnering progress for IMM-529 and IMM-124E as key catalysts, and watch for continued Travelan sales growth in North America. The strategic reset targeting profitability and reduced cash burn in FY27 is the key metric to track.
Price Chart
Executive Summary
Immuron Ltd reported FY26 preliminary results showing revenue up 5.9% to A$7.7M and net loss improved 26.4% to A$3.8M. Cash position strengthened to A$9.0M from A$2.8M. The company highlighted record Travelan sales, FDA IND approval for IMM-529, and a strategic reset toward profitability. However, the company remains pre-profit with accumulated losses of A$85.1M and the revenue growth is modest at 5.9% on a small base.
Key Facts
- Revenue from ordinary activities up 5.9% to A$7,713,601 (FY25: A$7,287,002)
- Net loss improved 26.4% to A$3,838,699 (FY25: A$5,215,987)
- Cash position increased to A$9,017,814 (FY25: A$2,830,526)
- Basic and diluted loss per share improved to (1.29) cents (FY25: (2.26) cents)
- Travelan Australia sales up 10% to A$5.7M; US sales up 7% in AUD (13% in USD)
- IMM-529 received U.S. FDA IND approval in November 2025
- Company engaged Pullan Consulting to support partnering IMM-529
- Shares outstanding increased to 322,848,081 from 233,959,013 (38% dilution)
- No dividends paid or declared
Financial Impact
Revenue up A$426,599 (+5.9%), net loss improved by A$1,377,288 (+26.4%), cash increased by A$6,187,288 (+218.6%)
Risk Factors
- Accumulated losses of A$85.1M with no path to near-term profitability
- 38% share dilution in FY26 from ATM facility and performance rights exercises
- Reliance on R&D tax incentive refunds (A$623,613 in FY26) for cash flow
- Clinical-stage pipeline (IMM-529, IMM-124E) requires partnering for development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-094657 |
| Document: 0001213900-26-094657-index-headers.html | 0001213900-26-094657 |
| Document: 0001213900-26-094657-index.html | 0001213900-26-094657 |
| Document: 0001213900-26-094657.txt | 0001213900-26-094657 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9300 | awaiting T+60 | — | $0.9300 (+0.00%) |
Oct 23, 2026 4d ago | 6-K | $0.9200 | awaiting T+60 | — | $0.9300 (+1.09%) |
Oct 23, 2026 4d ago | 424B5 | $0.9200 | awaiting T+60 | — | $0.9300 (+1.09%) |
Oct 21, 2026 6d ago | 6-K | $0.9490 | awaiting T+60 | — | $0.9300 (−2.00%) |
Oct 16, 2026 11d ago | 6-K | $0.9821 | awaiting T+60 | — | $0.9300 (−5.30%) |
Oct 13, 2026 14d ago | 6-K | $1.04 | awaiting T+60 | — | $0.9300 (−10.58%) |
Sep 24, 2026 4w ago | 20-F | $1.19 | awaiting T+60 | — | $0.9300 (−21.85%) |
Sep 24, 2026 4w ago | 6-K | $1.19 | awaiting T+60 | — | $0.9300 (−21.85%) |
Sep 21, 2026 5w ago | 6-K | $1.26 | awaiting T+60 | — | $0.9300 (−25.90%) |
Sep 4, 2026 7w ago | Press Release | $1.80 | awaiting T+60 | — | $0.9300 (−48.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers